Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)
Sponsor: Hospital for Special Surgery, New York
Summary
In this study, total knee replacement patients will be determined to be stiff or non-stiff preoperatively. Stiffness designation is determined by preoperative range of motion (if flexion is \< 100 degrees, or extension lag is \> 10 degrees). The stiff and non-stiff groups will both be randomized to two groups to receive either intravenous hydrocortisone or a placebo at 3 intervals postoperatively. Patients will be followed up with in hospital and via the phone on postoperative day (POD) 1 and 2, as well as 6 weeks, 6 months, 1 year, and 2 years postoperatively. Patients will also have blood drawn preoperatively in the OR, on POD1, at their 6 week followup, and at their 1 and 2 year follow ups. This blood will be processed and analyzed.
Official title: Effect of Intravenous Hydrocortisone on Range of Motion After Total Knee Arthroplasty: A Randomized Placebo-Controlled Trial With Nested Case-Control Study
Key Details
Gender
All
Age Range
18 Years - 83 Years
Study Type
INTERVENTIONAL
Enrollment
132
Start Date
2019-07-24
Completion Date
2026-05
Last Updated
2025-10-06
Healthy Volunteers
Yes
Conditions
Interventions
Hydrocortisone
Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
Dextrose 5% in water (D5W)
Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
Locations (1)
Hospital for Special Surgery
New York, New York, United States